1916505-13-9
Chemical Structure
HDAC-IN-31
- CAS No.: 1916505-13-9
- Formula:C25H24N4O2
- Molecular Weight:412.48
IUPAC Name: (E)-N-(2-aminophenyl)-4-((2-oxo-3-(pyridin-2-ylmethylene)piperidin-1-yl)methyl)benzamide
InChIKey: NBUJRTVDQYEPKP-CAPFRKAQSA-N
SMILES: O=C(NC1=CC=CC=C1N)C2=CC=C(CN3C(/C(CCC3)=C/C4=NC=CC=C4)=O)C=C2
Biological Activity: HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HDAC-IN-31 | HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
